Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Stem Cells Transl Med. 2013 Sep;2(9):690-702. doi: 10.5966/sctm.2013-0035. Epub 2013 Aug 9.
Tissue regeneration using progenitor cell-based therapy has the potential to aid in the healing of a diverse range of pathologies, ranging from short-gut syndrome to spinal cord lesions. However, there are numerous hurdles to be overcome prior to the widespread application of these cells in the clinical setting. One of the primary barriers to effective stem cell therapy is the hostile environment that progenitor cells encounter in the clinical injury wound setting. In order to promote cellular survival, stem cell differentiation, and participation in tissue regeneration, relevant cells and delivery scaffolds must be paired with strategies to prevent cell death to ensure that these cells can survive to form de novo tissue. The Bcl-2 protein is a prosurvival member of a family of proteins that regulate the mitochondrial pathway of apoptosis. Using several strategies to overexpress the Bcl-2 protein, we demonstrated a decrease in the mediators of apoptosis in vitro and in vivo. This was shown through the use of two different clinical tissue repair models. Cells overexpressing Bcl-2 not only survived within the wound environment at a statistically significantly higher rate than control cells, but also increased tissue regeneration. Finally, we used a nonintegrating minicircle technology to achieve this in a potentially clinically applicable strategy for stem cell therapy.
基于祖细胞的组织再生疗法具有帮助治愈多种病理疾病的潜力,从短肠综合征到脊髓损伤。然而,在这些细胞在临床环境中广泛应用之前,还需要克服许多障碍。有效干细胞治疗的主要障碍之一是祖细胞在临床损伤伤口环境中遇到的恶劣环境。为了促进细胞存活、干细胞分化和参与组织再生,相关细胞和输送支架必须与防止细胞死亡的策略相结合,以确保这些细胞能够存活并形成新的组织。Bcl-2 蛋白是一种调节细胞凋亡线粒体途径的蛋白质家族中的一种生存蛋白。我们使用几种过表达 Bcl-2 蛋白的策略,在体外和体内都证明了凋亡介质的减少。这是通过使用两种不同的临床组织修复模型来证明的。过表达 Bcl-2 的细胞不仅在伤口环境中的存活率明显高于对照细胞,而且还增加了组织再生。最后,我们使用非整合的微小环技术在一种潜在的临床应用的干细胞治疗策略中实现了这一点。